A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors

Table 5 Suggestion for the use of G-CSFs in individual cases. Secondary prevention dosage of G-CSFs

	Q15. DTX for squamous cell lung cancer^a
	n = 168
I recommend of secondary prophylactic administration of G-CSFs	73 (43.4)^b
After Grade 4 neutropenia developed, I recommend G-CSFs	23 (13.7)
After FN developed, I recommend G-CSFs	6 (3.6)
I do not recommend G-CSFs	66 (39.3)

DTX Docetaxel, G-CSF Granulocyte-Colony Stimulating Factor, FN Febrile Neutropenia
^aA 78-year-old man. You diagnosis of lung squamous cell carcinoma and started docetaxel alone therapy, but complication of febrile neutropenia was appeared. You confirmed a good tumor reduction effect, so you plan to treat the second course. What kind of suggestion do you do as a pharmacist?
^bNumber (percent)

ISSN: 2055-0294